Replies to post #24442 on Mymetics Corp (MYMX)

[Work Harder]

The non-human primate study received financial support from REACTing, the ANR (AM-CoV-Path), and the European Infrastructure TRANSVAC2 (730964). The funders had no role in study design, data
collection, data analysis, data interpretation, or data reporting.

https://www.cell.com/cell/pdf/S0092-8674(21)00078-7.pdf

AM-COV-Path aims at the development of a non-human primate model of the SArS-CoV-2 infection and disease.

Project coordinator

Mr. Roger Le Grand (French Atomic Energy and Alternative Energies Commission)

Partner

INSERM INSERM / Infection, Antimicrobials, Modeling, Evolution

https://translate.google.com/translate?hl=en&sl=fr&u=https://anr.fr/Projet-ANR-20-COVI-0021&prev=search&pto=aue

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota

https://www.tandfonline.com/doi/full/10.1080/19490976.2021.1893113

HS, RLG, and FT obtained funding (ANR/FRM AM-CoV-Path and ANR ACROBAT)

[Work Harder]

MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing

20 MAY 2019

The effort will provide vaccine process development training courses within TRANSVAC2, a collaborative infrastructure project under Horizon 2020.

https://www.emdgroup.com/en/news/transvac2-program-joining-20-05-2019.html

“Involvement in this project is a natural extension to our longtime focus on accelerating vaccine development and manufacturing,” said Udit Batra, CEO, MilliporeSigma. “Through the TRANSVAC2 initiative, we are able to lend our expertise in vaccine research and development in this critically important field.”

MilliporeSigma’s focus, to find effective ways to accelerate vaccine development and manufacturing, includes collaborative work with leading research institutes and industries to introduce new technologies that advance the global vaccine industry. For this initiative, MilliporeSigma is tapping its internal manufacturing expertise and process knowledge in viral vaccines and vectors.

Weill